New and emerging treatment of Staphylococcus aureus infections in the hospital setting

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 3, 2008, Pages 32-41

  Moreillon, Philippe ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Ceftobiprole; MRSA; PBP2a; Resistance; Review; SCCmec

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BETA LACTAM; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; LINEZOLID; METICILLIN; MIKAMYCIN B; OXAZOLIDINONE DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; PENICILLINASE; PEPTIDE DEFORMYLASE INHIBITOR; PROTEIN SYNTHESIS INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; RIFAMPICIN; TELAVANCIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BINDING AFFINITY; CELL MEMBRANE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; EPIDEMIC; ERADICATION THERAPY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INCIDENCE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; UNITED STATES;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEGIBACTERIA; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 40449119374     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01961.x     Document Type: Review

References (63)

1. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5: 2.
2. Noskin GA, Rubin RJ, Schentag JJ et al. The burden of Staphylococcus aureus infections on hospitals in the United States: An analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005; 165: 1756-1761.
3. Jevons MP. Celbenin-resistant staphylococci. BMJ 1961; i: 124-125.
4. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002; 99: 7687-7692.
5. Kluytmans-Vandenbergh MF, Kluytmans JA. Community-acquired methicillin-resistant Staphylococcus aureus: Current perspectives. Clin Microbiol Infect 2006; 12 (suppl 1): 9-15.
6. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12 (suppl 1): 16-23.
7. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence. Clin Infect Dis 2007; 44: 1543-1548.
8. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
9. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 1549-1555.
10. Ito T, Okuma K, Ma XX, Yuzawa H, Hiramatsu K. Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: Genomic island SCC. Drug Resist Updat 2003; 6: 41-52.
11. Chambers HF, Hartman BJ, Tomasz A. Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest 1985; 76: 325-331.
12. Ito T, Katayama Y, Asada K et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45: 1323-1336.
13. Ma XX, Ito T, Tiensasitorn C et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46: 1147-1152.
14. Okuma K, Iwakawa K, Turnidge JD et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40: 4289-4294.
15. Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004; 48: 2637-2651.
16. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1819-1827.
17. Couto I, de Lencastre H, Severina E et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri. Microb Drug Resist 1996; 2: 377-391.
18. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database Crit Care Med 2006; 34: 2588-2595.
19. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R et al. Reappraisal of community-acquired bacteremia: A proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002; 34: 1431-1439.
20. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007; 27: 227-249.
21. Chavez-Bueno S, Bozdogan B, Katz K et al. Inducible clindamycin resistance and molecular epidemiologic trends of pediatric community-acquired methicillin-resistant Staphylococcus aureus in Dallas, Texas. Antimicrob Agents Chemother 2005; 49: 2283-2288.
22. Infectious Diseases Society of America. Bad bugs, no drugs. 2004. http://www.idsociety.org/WorkArea/showcontent.aspx?id=5554
23. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis 2004; 38: 1279-1286.
24. Powers JH. Antimicrobial drug development - the past, the present, and the future. Clin Microbiol Infect 2004; 10 (suppl 4): 23-31.
25. Food and Drug Administration, US Department of Health and Human Services. 2004. http://www.fda.gov/cder/drug/infopage/linezolid/ default.htm
26. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother 2002; 50: 915-932.
27. Food and Drug Administration, US Department of Health and Human Services. 2007. http://www.fda.gov/cder/consumerinfo/druginfo/ synercid.htm
28. Chopra I. Glycylcyclines: Third generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1: 464-469.
29. Doan TL, Fung HB, Mehta D, Riska PF. Tigecycline: A glycylcycline antimicrobial agent. Clin Ther 2006; 28: 1079-1106.
30. European Medicines Agency (EMEA). Tygacil. European Public Assessment Report. 2006. http://www.emca.europa.eu/humandocs/Humans/EPAR/tygacil/ tygacid.htm
31. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic Gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 2006; 50: 2875 -2879.
32. Jones RN, Fritsche TR, Sader HS, Goldstein BP. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): Initial results from an international surveillance protocol. J Chemother 2005; 17: 593-600.
33. Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007; 2007: 406-409.
34. Cubist Pharmaceuticals, Inc. Cubicin IV. Prescribing information. 2007. http://www.cubicin.com/prescribe.pdf
35. Petersen PJ, Bradford PA, Weiss WJ, Murphy TM, Sum PE, Projan SJ. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant Gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-2601.
36. European Medicines Agency (EMEA). Cubicin. European Public Assessment Report. 2006. http://www.emea.europa.eu/humandocs/Humans/EPAR/cubicin/ cubicin.ht006D
37. Lofland D, Difuntorum S, Waller A et al. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother 2004; 53: 664-668.
38. Fritsche TR, Sader HS, Cleeland R, Jones RN. Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother 2005; 49: 1468 -1476.
39. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003; 111: 1265-1273.
40. Hartman BJ, Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol 1984; 158: 513-516.
41. Utsui Y, Yokota T. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985; 28: 397-403.
42. Song MD, Wachi M, Doi M, Ishino F, Matsuhashi M. Evolution of an inducible penicillin-target protein in methicillin-resistant Staphylococcus aureus by gene fusion. FEBS Lett 1987; 221: 167-171.
43. de Jonge BL, Tomasz A. Abnormal peptidoglycan produced in a methicillin-resistant strain of Staphylococcus aureus grown in the presence of methicillin: Functional role for penicillin-binding protein 2A in cell wall synthesis. Antimicrob Agents Chemother 1993; 37: 342-346.
44. Pinho MG, de Lencastre H, Tomasz A. An acquired and a native penicillin-binding protein cooperate in building the cell wall of drug-resistant staphylococci. Proc Natl Acad Sci USA 2001; 98: 10886-10891.
45. Berger-Bachi B. Expression of resistance to methicillin. Trends Microbiol 1994; 2: 389-393.
46. de Lencastre H, de Jonge BL, Matthews PR, Tomasz A. Molecular aspects of methicillin resistance in Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 7-24.
47. Katayama Y, Zhang HZ, Chambers HF. PBP 2a mutations producing very-high-level resistance to beta-lactams. Antimicrob Agents Chemother 2004; 48: 453-459.
48. Moreillon P, Franciolli M, Cantoni L, Bille J, Glauser MP. Beta-lactam antibiotics active against methicillin-resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1165-1166.
49. Franciolli M, Bille J, Glauser MP, Moreillon P. Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis 1991; 163: 514-523.
50. Hirano L, Bayer AS. Beta-lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother 1991; 35: 685-690.
51. Chambers HF. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob Agents Chemother 1995; 39: 462-466.
52. Que YA, Entenza JM, Francioli P, Moreillon P. The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis 1998; 177: 146-154.
53. Lim D, Strynadka NC. Structural basis for the beta lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat Struct Biol 2002; 9: 870-876.
54. Tomasz A. 'Intelligence coup' for drug designers: Crystal structure of Staphylococcus aureus beta-lactam resistance protein PBP2A. Lancet 2003; 361: 795-796.
55. Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2005; 5: 479-489.
56. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: The first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16: 419-429.
57. Glinka TW. Novel cephalosporins for the treatment of MRSA infections. Curr Opin Investig Drugs 2002; 3: 206-217.
58. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MG, Then RL. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 2001; 45: 825-836.
59. Deshpande L, Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn Microbiol Infect Dis 2004; 50: 73-75.
60. Zbinden R, Punter V, von Graevenitz A. In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters. Antimicrob Agents Chemother 2002; 46: 871-874.
61. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob Agents Chemother 2008; 52: 37-44.
62. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647-655.
63. Lipsky BA, Berendt AR, Deery HG et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39: 885-910.